Eko Devices is a company.
Key people at Eko Devices.
Eko Devices was founded by Connor Landgraf (Cofounder & CEO).
Key people at Eko Devices.
Eko Devices was founded by Connor Landgraf (Cofounder & CEO).
Eko Health (formerly Eko Devices) is a commercial-stage cardiac health technology company that develops AI-powered digital stethoscopes, ECG devices, telehealth software, and clinical decision support tools to enable earlier detection and monitoring of heart and lung diseases.[1][2][3][6] It serves over 600,000 healthcare providers globally across thousands of hospitals and facilities, solving the problem of inaccurate or missed diagnoses in noisy environments, remote settings, and underdiagnosed conditions like murmurs, atrial fibrillation (AFib), and low ejection fraction (Low EF).[2][3][6][7] With over 650,000 devices sold—the world's largest connected digital stethoscope network—the company has raised $95.5 million in funding, including a $65 million Series C in 2020, and powers virtual care in over 800 U.S. hospitals through flexible telehealth integrations.[1][2]
Eko Health was founded in 2013 in the Bay Area by Connor Landgraf, who identified the limitations of traditional analog stethoscopes during his senior thesis at UC Berkeley while interviewing cardiologists.[1][3] Landgraf recruited classmates Tyler Crouch and Jason Bellet, and the team participated in accelerator programs to launch their first FDA-cleared CORE™ Digital Stethoscope (Gen 1), which combined analog and digital functionality.[3] Early traction came from partnerships with strategic players like 3M (co-developing the Littmann® CORE Digital Stethoscope), the National Institutes of Health (NIH), and Mayo Clinic, alongside steady growth fueled by the COVID-19 demand for telehealth.[1][3] Pivotal moments include multiple FDA clearances for AI algorithms (e.g., Low EF detection in 15 seconds, EFAST foundation model) and AMA Category III CPT code for its SENSORA™ platform.[3]
Eko Health rides the wave of AI-driven digital health transformation, particularly in cardiovascular and pulmonary care, where traditional diagnostics lag amid rising chronic disease burdens and telehealth adoption post-COVID.[1][2] Its timing aligns with exploding demand for virtual exams—addressing auscultation gaps in remote workflows—and market forces like EHR integration, wearable proliferation, and underdiagnosed conditions (e.g., Low EF affecting millions).[1][4] By partnering with 3M, NIH, Mayo Clinic, and biopharma for data sets and biomarkers, Eko influences the ecosystem through the largest professional AI cardiology install base, enabling scaled screening, therapy development, and reduced in-person visits while bridging consumer wearables and clinical-grade tools.[1][2][4][5]
Eko Health is poised for expansion as AI foundation models like EFAST and telehealth integrations deepen penetration in health systems, biopharma trials, and global markets, potentially capturing more of the $10B+ digital stethoscope and cardiac monitoring space.[2][3][4] Trends like remote patient monitoring regulations, AI regulatory tailwinds (e.g., more FDA clearances), and cardiopulmonary therapy demand will accelerate growth, evolving Eko from device maker to comprehensive early-detection platform.[1][3] Like Ring's doorbell reinvention, Eko's stethoscope upgrade could redefine ubiquitous medtech, amplifying its ecosystem influence as virtual care becomes standard.[5]